文献速递免疫规划传染病防控与疫情报告

灭活肠道病毒71型疫苗对儿童手足口病的长期保护:模型研究

Long-term protection of an inactivated enterovirus type 71 vaccine against hand, foot, and mouth diseases in children: a modelling study.
PubMed 文献 · Vaccine · 2026-02-05

该研究基于3期试验中免疫原性亚组5年随访的中和抗体数据,构建数学模型预测EV71疫苗20年长期保护效果。模型预测两剂400U灭活EV71疫苗在20年时保护效力仍达72.57%(95%CI:71.35%-73.80%),高应答者20年保护率为75.58%。

要点

  • 两剂400U灭活EV71疫苗预测20年保护效力为72.57%(95%CI:71.35%-73.80%)。
  • 高应答者20年保护率75.58%,中、低应答者分别为65.09%和64.99%。
  • 模型预测GMT从第1月168.30降至第240月68.04(95%CI:60.38-76.68)。

核心结论

  • 在当前中国EV71流行条件下,两剂灭活EV71疫苗可提供至少20年、超过72%的持久保护。

研究设计与样本

  • 基于3期随机对照试验中免疫原性亚组5年中和抗体随访数据构建数学模型。
  • 采用分段幂律模型拟合抗体衰减,Bootstrap抽样10000次生成模拟数据集。
  • 引入2017年前后差异暴露率的动态暴露模拟,并用Scaled Logit模型关联中和抗体滴度与保护效力。
  • 按初始抗体滴度将人群分为高、中、低应答者进行分层分析。

主要发现

  • 预测GMT在第1月为168.30(95%CI:139.76-202.67),第6月111.28(95%CI:93.15-132.95)。
  • 预测GMT在第12月为93.80(95%CI:79.12-111.20),第240月68.04(95%CI:60.38-76.68)。
  • 预测保护效力第1月为80.19%(95%CI:78.69%-81.70%),第20年降至72.57%(95%CI:71.35%-73.80%)。
  • 分层分析显示高应答者第20年保护率75.58%,中应答者65.09%,低应答者64.99%。

临床怎么用

  • 可为EV71疫苗长期免疫策略和加强免疫决策提供模型参考。
  • 对初始抗体应答较低者,需关注其长期保护力相对下降。

局限性

  • 预测基于模型模拟和5年抗体随访数据外推至20年,非直接长期随访观察。
  • 保护效力关联依赖Scaled Logit模型假设及动态暴露模拟设定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Despite the availability of enterovirus type 71 (EV71) vaccines, evidence on long-term protection remains limited. We aimed to establish a mathematical model for predicting the 20-year long-term protection of the EV71 vaccine. METHODS: We utilized data from a phase 3 trial in which infants and young children were randomized to receive either two doses of 400 U EV71 vaccine or placebo. Neutralizing antibody data (NTAb) were obtained from the immunogenicity subpopulation who were followed for 5 years. We compared candidate decay models using Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC), and selected the Segmented Power-law Model to fit antibody decay kinetics. Simulated datasets were generated via 10,000 iterations of Bootstrap sampling. We introduced dynamic exposure simulation with differential exposure rates before and after 2017, and applied a Scaled Logit Model to establish the association between NTAb titers and protective efficacy. Additionally, we performed stratified analysis by dividing the population into High, Medium, and Low responders based on initial antibody titers. Uncertainty was quantified using 95% confidence intervals (CI). RESULTS: The predicted geometric mean titers (GMT) were 168.30 (95% CI: [139.76, 202.67]) at Month 1, 111.28 (95% CI: [93.15, 132.95]) at Month 6, 93.80 (95% CI: [79.12, 111.20]) at Month 12, and 68.04 (95% CI: [60.38, 76.68]) at Month 240. The model predicts that the EV71 vaccine provides a protective efficacy of 80.19% (95% CI: [78.69%, 81.70%]) at Month 1, declining to 72.57% (95% CI: [71.35%, 73.80%]) at Year 20. Stratified analysis revealed that High Responders maintained 75.58% protection at Year 20, compared to 65.09% for Medium and 64.99% for Low Responders. CONCLUSION: Under the current EV71 epidemic conditions in China, the two-dose regimen of the inactivated EV71 vaccine provides durable protection exceeding 72% for at least 20 years.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ma X, Jin L, Li J, et al. Long-term protection of an inactivated enterovirus type 71 vaccine against hand, foot, and mouth diseases in children: a modelling study. Vaccine. 2026. PMID: 41650673. doi:10.1016/j.vaccine.2026.128286

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。